Farowski, F
Bücker, V
Vehreschild, J J
Biehl, L
Cruz-Aguilar, R
Scheid, C
Holtick, U
Jazmati, N
Wisplinghoff, H
Cornely, O A
Vehreschild, M J G T
Article History
Received: 11 May 2017
Revised: 2 August 2017
Accepted: 2 August 2017
First Online: 13 November 2017
Competing interests
: FF received travel grants from Astellas and MSD. MJGTV is a consultant to Berlin Chemie, MSD/Merck and Astellas Pharma; has served at the speakers’ bureau of Astellas Pharma, Basilea, Gilead Sciences, Merck/MSD, Organobalance and Pfizer; received research funding from 3M, Astellas Pharma, DaVolterra, Gilead Sciences, Merck/MSD, Organobalance and Seres Therapeutics. JJV is a consultant to Basilea, MSD/Merck and Astellas Pharma; has served at the speakers’ bureau of: Basilea, Pfizer, Merck/MSD, Gilead Sciences and Astellas Pharma; received research funding from Astellas Pharma, Basilea, Merck/MSD and Gilead Sciences. LMB has received lecture honoraria from Astellas and MSD and travel grants from 3M and Gilead. NJ received payments for lectures from MSD, travel grant from IMDx (Qiagen) and research funding from DaVolterra. OAC is supported by the German Federal Ministry of Research and Education and the European Commission, and has received research grants from, is an advisor to, or received lecture honoraria from, Actelion, Amplyx, Anacor, Aranis, Astellas, AstraZeneca, Basilea, Bayer, Cidara, Da Volterra, Duke University (NIH UM1AI104681), F2G, Gilead, GSK, Janssen Pharmaceuticals, Leeds University, Matinas, MedPace, Melinta Therapeutics, Menarini Ricerche, Merck/MSD, Miltenyi, Paratek Pharmaceuticals, Pfizer, Rempex, Roche, Sanofi Pasteur, Scynexis, Seres, Summit, The Medicine Company, Vical, Vifor. The remaining authors declare no conflict of interest.